KEXING BIOPHARM CO.(SH:688136) Shang Hai Zheng Quan Bao·2025-09-14 20:59Core Viewpoint - The announcement details a share transfer plan by Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. to transfer 10,062,800 shares of Kexing Pharmaceutical, representing 5.00% of the total share capital, through a non-public inquiry transfer process [3][7]. Group 1: Share Transfer Details - The total number of shares to be transferred is 10,062,800, which accounts for 5.00% of the company's total share capital [3][7]. - The transfer is organized by China International Capital Corporation (CICC) and is not conducted through public trading methods [3][10]. - The receiving party must be an institutional investor with appropriate pricing capabilities and risk tolerance [3][10]. Group 2: Seller Information - The seller, Shenzhen Keyi Pharmaceutical, is the controlling shareholder of Kexing Pharmaceutical, with a shareholding exceeding 5% [3][4]. - The seller has confirmed that the shares are free from any transfer restrictions and have been released from lock-up [4][5]. Group 3: Pricing Mechanism - The minimum transfer price will not be lower than 70% of the average trading price of the company's shares over the 20 trading days prior to the issuance of the subscription invitation [8]. - The pricing determination will follow a priority system based on subscription price, quantity, and time of submission [9]. Group 4: Company Status - Kexing Pharmaceutical does not have any undisclosed operational risks or potential changes in control related to this share transfer [11]. - There are no other significant undisclosed matters concerning the company [11].